Skip to main content

Patent Landscape of Countermeasures Against Smallpox and Estimation of Grant Attraction Capability Through Patent Landscape Data

Buy Article:

$68.00 + tax (Refund Policy)

The study was concerned with countermeasures against a possible smallpox outbreak. In the process of assessment 18 landscaping sectors were defined and described, the advantages and drawbacks of the corresponding countermeasures being reviewed. The data of the previously published influenza landscape were revisited. The current economic climate of deficit cutting (austerity) also puts emphasis on the optimization of capital investment. We used the materials of the landscape to define and analyze metrics of capital placement optimization. Value score was obtained by fitting patent landscape internals to the sale price of individual patents. Success score was obtained as a product of α-priori parameters that measure likelihood of emergence of a marketable product in a technological sector. Both scores were combined in a qualitative metric. Our methodology defined weight as a product of the sector size by the success score. We hypothesized - based on the material of two landscapes- that a life cycle of a technology begins in IP space with a high patent quality low volume “bud” of low weight, reaches maximum weight and then weight falls again when the technology becomes outdated. The weight and the annual dynamic of weight can serve a measure of investment risk and return. In this report, we modeled investment by issue of government grants or purchase of patents by government. In the smallpox landscape the number of patents purchased by government agencies was the highest in the sectors with the highest weight and the trend was confirmed by the count of NIH grants issued in support of the technological sectors. In the influenza landscape only grant issue count was statistically meaningful and the trend was also confirmed. To better fit the grant support levels, the weight expression was optimized by using training coefficients.

We propose to use value scores for evaluation of individual patent publications/company portfolios and to use weights for assessment of technological sectors. Such a combination of automated analytical tools may lead to optimized allocation of capital and is intended to support the decisions taken by human experts.



Keywords: 4-PBA; ACAM2000; ANPs; APMV; Acanthamoeba polyphaga; Avian paramyxovirus; CEV; CF; CMX001; CTL; Chordopoxvirinae; Cidofovir; Cowpox virus; CpG ODN; DNA; Dengue fever; Deoxyspergualin; Dryvax; EC; EEV; Geldanamycin; Herpes virus; IEV; IFN; LAIC; LCR; LL-37; Lister; MVA; Modified Vaccinia virus; Monkeypox; Multi-Pathway High Throughput Assay; NCLDV; Orthopoxvirus; PCR; Plasmodium falciparum; Polyvalent vaccines; Poxiviridae; RIC; ROI; SIGA; ST-246; Tyrosine kinase; US6869793; UTI- beta; VIG (vaccinia immunoglobulines); Vaccine Adjuvants; Variola; WIPOC; WO04043490A; a-priori; antivirals; aphthous stomatitis; arrays sensors; austerity; chlorprothixene; glycoalkaloids; hemagglutinin genes; hepatitis-A; hrVCP; human BCDF; immature virion; immunological assays; immunostimulating glycopeptide; investment efficiency; mimivirus; mousepox; osteoblast; osteocyte apoptosis; patent landscape; poxvirus; prophylaxis; reverse transcriptase; smallpox; spectral analysis; technological sectors; vaccines; virokines

Document Type: Research Article

Publication date: 01 November 2010

More about this publication?
  • Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content